Alternatives to Valganciclovir If You Can't Fill Your Prescription

Valganciclovir (Valcyte) has long been the standard oral antiviral for preventing and treating cytomegalovirus (CMV) in transplant recipients and patients with AIDS. But what happens if your pharmacy can't fill it, your insurance won't cover it, or you're experiencing intolerable side effects? The good news: you're not out of options.

This guide reviews the main alternatives to valganciclovir, their key differences, and important considerations for switching. Always consult your transplant physician or infectious disease specialist before changing your CMV medication — these are complex drugs that require careful management.

Why Someone Might Need a Valganciclovir Alternative

There are several common reasons patients or providers look for alternatives to valganciclovir:

• Severe myelosuppression (neutropenia, anemia, thrombocytopenia) requiring discontinuation
• Valganciclovir-resistant CMV infection (UL97 or UL54 mutations)
• Severe kidney impairment making dosing difficult or unsafe
• Insurance coverage gaps or cost-related access issues
• Temporary unavailability at local pharmacies

Alternative 1: Letermovir (Prevymis)

Letermovir is the most discussed alternative to valganciclovir for CMV prophylaxis in transplant recipients. It works by a completely different mechanism — it inhibits the CMV terminase complex rather than DNA polymerase — and has no cross-resistance with valganciclovir or ganciclovir.

FDA-approved uses of letermovir (Prevymis):

• Prevention of CMV disease in adult allogeneic stem cell transplant recipients (approved 2017)
• Prevention of CMV disease in adult high-risk kidney transplant recipients (approved 2023)

Key advantages over valganciclovir: Letermovir does not suppress bone marrow, so it does not cause the neutropenia, anemia, or thrombocytopenia associated with valganciclovir. Clinical trial data show letermovir had a 26% rate of leukopenia/neutropenia versus 64% for valganciclovir in kidney transplant recipients. It also does not require dose adjustment for renal impairment.

Limitations: Letermovir has a low barrier to resistance if used for active treatment and is not effective against herpes simplex virus (HSV) or varicella zoster virus (VZV), unlike valganciclovir. It also has significant drug interactions with calcineurin inhibitors like cyclosporine. Letermovir is only FDA-approved for prophylaxis — not treatment of active CMV disease.

Alternative 2: IV Ganciclovir (Cytovene)

Intravenous ganciclovir is the parent drug of valganciclovir and is preferred for severe or life-threatening CMV disease and for CMV in stem cell transplant recipients who require hospitalization. It is also the standard initial induction therapy for CMV retinitis.

Because it is administered intravenously, ganciclovir is not a practical outpatient substitute for oral valganciclovir. However, it is an important option when oral therapy is not possible (patients who cannot take medications by mouth, are hospitalized, or have very severe disease).

Alternative 3: Maribavir (Livtencity)

Maribavir (brand name Livtencity) is an oral antiviral approved specifically for CMV infections that are resistant or refractory to ganciclovir, valganciclovir, foscarnet, or cidofovir in adult transplant recipients. It works by inhibiting the CMV UL97 kinase with a unique mechanism that does not overlap with valganciclovir's target.

Maribavir is not a first-line alternative — it is reserved for treatment-resistant infections. But for patients who have developed valganciclovir-resistant CMV, it provides an important oral treatment option. It is dosed at 400 mg twice daily and is generally better tolerated from a hematologic standpoint than ganciclovir or valganciclovir.

Alternative 4: Foscarnet (Foscavir) and Cidofovir (Vistide)

Foscarnet and cidofovir are IV agents reserved for CMV that is resistant to ganciclovir/valganciclovir or when those drugs cannot be tolerated. Both are highly nephrotoxic — foscarnet also causes severe electrolyte abnormalities — and typically require hospitalization or close monitoring. They are not practical first-line substitutes for oral valganciclovir but are important backup options.

What to Do If You Can't Get Valganciclovir Right Now

Do not simply skip doses while searching for an alternative. CMV can reactivate quickly in immunocompromised patients, and the consequences — end-organ disease, graft loss, vision loss — can be severe and permanent. Contact your prescriber or transplant center immediately if you cannot fill your prescription. They will coordinate the appropriate next step, whether that is emergency dispensing, a bridge supply, or a switch to an alternative therapy.

If the issue is simply finding a pharmacy with valganciclovir in stock, medfinder can call pharmacies near you to find which ones can fill your prescription.

If cost is the barrier, read our guide on How to Save Money on Valganciclovir in 2026 for coupons, patient assistance programs, and insurance tips.